PRODUCTS & SERVICES
Custom Oligonucleotides Services
Innovative Enterprise Vienna, a joint event of the European Commission and the Austrian EU Council Presidency, primarily aims to support highly innovative start-up and scale-up enterprises in their successful new markets’ entry. This year’s conference specifically contributed to gaining better insight into the requirements of the present European financing opportunities for innovations (InnovFin, Horizon 2020, Eurostars, EFSI) and future ones (Horizon Europe, Invest EU). The programme focused on two key elements: general risk financing for highly innovative enterprises, and financing by the European Innovation Council, in particular. Also, the organizers chose the best “Seal of Excellence” projects to show parallel finance pitching sessions in practice.
Only six startups out of 300 were chosen for the open deal session and MultiplexDX was among them! The company leader (Dr. Pavol Cekan) and the main investor (Michal Nespor from Crowdberry) were given the eight-minute pitching time to present the company and answer the questions. The open deal session was also broadcasted online and seen by hundreds of investors worldwide. Immediately after the pitch Norwegian and Italian VC funds contacted MultiplexDX with potential interest to invest.
Dr. Pavol Cekan, Founder and CEO of MultiplexDX, comments:
“We were very excited to be selected from the best Horizon 2020 start-ups to give a pitch at this amazing event! Attended by high-level policy makers, investors, leading companies and pitching experts, the event was definitely another great experience which will lead to new investment and strategic partnership opportunities for MultiplexDX in the near future!”
Another clear target of Innovative Enterprise Vienna 2018 was to make the win-win effect from European and national level collaboration more visible, as well as to support further improvements of innovation funding in Europe. Consequently, the event will contribute to the “innovation element” of the forthcoming "Horizon Europe".
Innovative Enterprise is an initiative of the European Commission aimed at raising awareness of the European Union’s investment programmes, such as InnovFin and the European Fund for Strategic Investments, instruments at the national and local level, as well as alternative financing sources, such as crowdfunding. This international conference brings together high-level policymakers, financial intermediaries, and representatives of the research, innovation, and business communities to discuss how to access monies for research, innovation, and SMEs.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.